However, CureVac won't need Tesla's Midas touch to succeed with its bigger story. It's one of only three companies with COVID-19 vaccine candidates currently in phase 2 testing. The other two are Chinese drugmakers. This puts CureVac's vaccine candidate CVnCoV behind only five others in late-stage testing that could be commercialized in major Western markets.
CureVac plans to advance CVnCOV into a pivotal phase 2b/3 clinical study by the end of 2020. If all goes well, the biotech seems likely to become one of the biggest COVID vaccine winners.
The company recently lined up an agreement with the European Commission to supply up to 225 million doses of CVnCOV (assuming it secures regulatory approval). The deal includes an option for the EC to buy an additional 180 million doses. Although no financial details were revealed, CureVac likely stands to make several billion dollars in 2021 if CVnCOV is proven to be safe and effective in late-stage testing.
CVnCOV can be stored at standard refrigerator temperatures for up to three months and for up to 24 hours at room temperature. This could give it an advantage over vaccines such as Pfizer's and BioNTech's BNT162b2, which must be stored at ultracold temperatures.
One to watch
Success for CVnCOV could bode well for the rest of CureVac's mRNA pipeline. The company is evaluating a rabies vaccine and two cancer immunotherapy candidates in phase 1 clinical studies. CureVac also has several other preclinical programs.
It's still too early to know for sure if CVnCOV will achieve similar efficacy to the results announced by Pfizer and Moderna. However, CureVac is without question a biotech stock for investors to keep on their radars.
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Tesla. The Motley Fool has a disclosure policy.
Recent CVAC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/13/2024 08:15:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/12/2024 08:33:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 08:15:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 08:30:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 08:25:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 08:20:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 08:15:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2024 08:22:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 08:56:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 11:54:18 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 08:27:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 08:09:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 02:02:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 09:15:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2024 08:19:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2024 07:41:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 09:30:46 PM
- CureVac Shares Hit All-Time Low on German Patent Court Ruling • Dow Jones News • 12/19/2023 05:12:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2023 09:15:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 08:45:30 PM
- Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 10/12/2023 08:15:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/28/2023 08:30:35 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM